"Offering cancer screening to insurers, employers, and employees is a groundbreaking part of Reframe Cancer’s growth and something we have spearheaded since becoming CQC registered."
- Mark Stephenson, CEO of Reframe Cancer
Reframe Cancer’s screening proposition includes screenings for bowel, cervical, and prostate cancer via at home testing, as well as lung and breast cancer in clinics, and skin cancer via mobile app SkinVision. The platform delivers personalised NHS screening eligibility, cancer risk assessments, and health guidance, with results followed up by its cancer nurse specialists.
Furthermore, Reframe Cancer’s flexible models can be used to suit businesses, with self-pay, part funded by employer/policy, fully funded by employer/policy, or included as part of a flexible benefits package available.
To support this launch, Nikki Cannon (pictured) has been appointed as head of cancer screening. In the past, she has worked extensively with the NHS, third sector, and healthcare providers. Nikki led the transformation of personalised care and survivorship at Guy’s and St. Thomas’ NHS Trust and developed a new cancer workforce engagement framework at Macmillan Cancer Support.
“I have always been passionate about improving the outcomes and experiences for people affected by cancer through earlier diagnosis and access to better treatments. Providing this service through Reframe Cancer will enable greater access to screening at a younger age for patients […] being able to do this and offer it as a workplace benefit could save so many lives,” she said.
Nikki also joins Reframe Cancer’s clinical advisory board, led by Dr Seema Dadhania. Insights from the board help inform product developments and patient care. She joins Dr Adam Wright (Neko Health), Dr Amar Maroo, Dr Cheng Boon, Jonathan Gregory (Macmillan Cancer Support), and Danny Bell (Macmillan Cancer Support).
Mark Stephenson, CEO of Reframe Cancer, added: “I’m delighted that Nikki is leading our cancer screening proposition. She understands the complexities of the NHS and private healthcare systems like no one else. Early detection and cancer screening is a vital component of tackling the rising UK cancer numbers, as almost half of all cancer cases are diagnosed at stages 3 and 4, which is too late.
“Enabling greater access to cancer screening also supports the NHS Long Term Plan, which aims for the proportion of cancers diagnosed at stages 1 and 2 to rise from around half to three-quarters of cancer patients by 2028.”
